| Ytd | 16.76% | |
| 1y | 5.49% |
| Open | 14.00 | Prev Close | 14.05 | Low | 14.00 | High | 14.59 | Mkt Cap | 393.71M |
| Vol | 64.50K | Avg Vol | 124.01K | EPS | -1.08 | P/E | N/A | Forward P/E | N/A |
| Beta | 2.09 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 14.83 | 200-d Avg | 12.29 | 1yr Est | 0.00 |
CARL News
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the
CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the
Carlsmed (NASDAQ:CARL) affirms FY2026 sales outlook from $74.000 million-$78.000 million to $74.000
Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology co
CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or th
CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a
CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or th
Carlsmed NASDAQ: CARL outlined its strategy for expanding its personalized spine-surgery platform, c
Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises
Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript
Carlsmed NASDAQ: CARL reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 milli
Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus E
Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $72.000 million-$77.000 million to $74.000 m
Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026
Centers for Medicare & Medicaid Services (CMS) Fiscal Year 2027 Inpatient Final Rule creates three n
CARLSBAD, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the
CARLSBAD, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess
Needham analyst David Saxon initiates coverage on Carlsmed (NASDAQ:CARL) with a Buy rating and an
The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empiri
Carlsmed, Inc. (CARL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock.
Carlsmed, Inc. (CARL) Q1 2026 Earnings Call Transcript
Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus E
First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 r
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and a